Epigenomics in respiratory epithelium carcinogenesis: Prevention and therapeutic challenges

Cancer Treatment Reviews

Volumn 33, Issue 3, 2007, Pages 284-288

  Karamouzis, Michalis V ^a   Konstantinopoulos, Panagiotis A ^a,b   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Acetylation; Epigenomics; Histone code; Lung cancer; Methylation

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; 4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; 5,6 DIHYDROXYAZACYTIDINE; APICIDIN; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; BUTYRIC ACID; CINCHOCAINE; CRA 024781; CYTOTOXIC AGENT; DEPEUDECIN; DEPSIPEPTIDE; DNA METHYLTRANSFERASE INHIBITOR; EPIGALLOCATECHIN GALLATE; EPOXIDE; FR 901228; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; HYDROXAMIC ACID; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PROCAINAMIDE; TRAPOXIN A; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

CANCER CELL; CANCER GROWTH; CELL DIFFERENTIATION; CLINICAL TRIAL; CPG ISLAND; DNA DETERMINATION; DNA METHYLATION; DNA REPLICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVITY; EPIGENETICS; GENE ACTIVATION; GENE MUTATION; GENE SILENCING; GENE TARGETING; GENETIC CODE; GENOME ANALYSIS; HUMAN; LOW DRUG DOSE; LUNG CARCINOGENESIS; MONOTHERAPY; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; ONCOGENE; PRECANCER; PROTEIN PROCESSING; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT CANCER; REVIEW; TRANSCRIPTION REGULATION;

DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONE DEACETYLASES; HISTONES; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; RESPIRATORY MUCOSA;

EID: 34248650471     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.01.003     Document Type: Review

References (38)

1. Jaenisch R., and Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 33 Suppl. (2003) 245-254
2. Feinberg A.P., Ohlsson R., and Henicoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 7 (2006) 21-33
3. Vincenzi B., Schiavon G., Silletta M., Santini D., Perrone G., Di Marino M., et al. Cell cycle alterations and lung cancer. Histol Histopathol 21 (2006) 423-435
4. Bowman R.V., Yang I.A., Semmler A.B.T., and Fong K.M. Epigenetics of lung cancer. Respirology 11 (2006) 355-365
5. Santos-Rosa H., and Caldas C. Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 41 (2005) 2381-2402
6. Kishimoto M., Kohno T., Okudela K., Otsuka A., Sasaki H., Tanabe C., et al. Mutations and deletions of the CBP gene in human lung cancer. Clin Cancer Res 11 2 Pt. 1 (2005) 512-519
7. Iyer N.G., Ozdag H., and Caldas C. p300/CBP and cancer. Oncogene 23 (2004) 4225-4231
8. Singh R.R., and Kumar R. Steroid hormone receptor signaling in tumorigenesis. J Cell Biochem 96 (2005) 490-505
9. Johnson S.A., Dubeau L., White R.J., and Johnson D.L. The TATA-binding protein as a regulator of cellular transformation. Cell Cycle 2 (2003) 442-444
10. Karamouzis M.V., Papadas T., Varakis I., Sotiropoulou-Bonikou G., and Papavassiliou A.G. Induction of the CBP transcriptional co-activator early during laryngeal carcinogenesis. J Cancer Res Clin Oncol 128 (2002) 135-140
11. Inche A.G., and La Thangue N.B. Chromatin control and cancer-drug discovery: realizing the promise. Drug Discov Today 11 (2006) 97-109
12. Yoo C.B., and Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5 (2006) 37-50
13. Zhang K., and Dent S.Y. Histone modifying enzymes and cancer: going beyond histones. J Cell Biochem 96 (2005) 1137-1148
14. Zhu W.G., Lakshmanan R.R., Beal M.D., and Otterson G.A. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 61 (2001) 1327-1333
15. Santos E.S., Raez L.E., DeCesare T., and Singal R. DNA methylation: its role in lung carcinogenesis and therapeutic implications. Expert Rev Anticancer Ther 5 (2005) 667-679
16. Wilson I.M., Davies J.J., Weber M., Brown C.J., Alvarez C.E., MacAulay C., et al. Epigenomics: mapping the methylome. Cell Cycle 5 (2006) 155-158
17. Robertson K.D. DNA methylation and human disease. Nat Rev Genet 6 (2005) 597-610
18. Lin R.K., Hsu H.S., Chang J.W., Chen C.Y., Chen J.T., and Wang Y.C. Alteration of DNA methyltransferases contributes to 5′CpG methylation and poor prognosis in lung cancer. Lung Cancer 55 (2005) 205-213
19. Kim H., Kwon Y.M., Kim J.S., Han J., Shim Y.M., Park J., et al. Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer 107 (2006) 1042-1049
20. Vallböhmer D., Brabender J., Yang D., Schneider P.M., Metzger R., Danenberg K.D., et al. DNA methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-small-cell lung cancer: association and prognostic value. Clin Lung Cancer 8 (2006) 39-44
21. Belinsky S.A. Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 26 (2005) 1481-1487
22. Belinsky S.A., Liechty K.C., Gentry F.D., et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 66 (2006) 3338-3344
23. Dammann R., Strunnikova M., Schagdarsurengin U., et al. CpG island methylation and expression of tumour-associated genes in lung carcinoma. Eur J Cancer 41 (2005) 1223-1236
24. Rauch T., Li H., Wu X., and Pfeifer G.P. MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-containing genes in lung cancer cells. Cancer Res 66 (2006) 7939-7947
25. Tada Y., Brena R.M., Hackanson B., Morrison C., Otterson G.A., and Plass C. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J Natl Cancer Inst 98 (2006) 396-406
26. Buggy J.J., Cao Z.A., Bass K.E., et al. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther 5 (2006) 1309-1317
27. Konstantinopoulos P.A., and Papavassiliou A.G. Chromatin-modulating agents as epigenetic anticancer drugs - 'the die is cast'. Drug Discov Today 11 (2006) 91-93
28. Aparicio A. The potential of histone deacetylase inhibitors in lung cancer. Clin Lung Cancer 7 (2006) 309-312
29. Villar-Garea A., and Esteller M. Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer 112 (2004) 171-178
30. Schrump D.S., Fischette M.R., Nguyen D.M., Zhao M., Li X., Kunst T.F., et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 12 (2006) 5777-5785
31. Schwartsmann G., Schunemann H., Gorini C.N.F., Ferreira Filho A.F., Garbino C., Sabini G., et al. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drugs 18 (2000) 83-91
32. Digel W., and Lubbert M. DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results. Crit Rev Oncol Hematol 55 (2005) 1-11
33. Belinsky S.A. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 4 (2004) 707-717
34. Kim J.S., Kim J.W., Han J., Shim Y.M., Park J., and Kim D.H. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res 66 (2006) 4049-4054
35. Toyooka S., Tokumo M., Shigematsu H., et al. Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res 66 (2006) 1371-1375
36. Braiteh F., Soriano A., Luis C.H., David H.S., Ng C., Garcia-Manero G., et al. Phase I study of low-dose hypomethylating agent azacitidine (5-AC) combined with the histone deacetylase inhibitor valproic acid (VPA) in patients with advanced cancers. J Clin Oncol 24 Suppl (2006) 3060
37. Suzuki M., Sunaga N., Shames D.S., Toyooka S., Gazdar A.F., and Minna J.D. RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res 64 (2004) 3137-3143
38. Karamouzis M.V., and Papavassiliou A.G. Retinoid receptor cross-talk in respiratory epithelium cancer chemoprevention. Trends Mol Med 11 (2005) 10-16